MichaelJFisherMD

Pediatric Hematology & Oncology • Philadelphia, PA

Pediatric Neuro-Oncology

Associate Professor, Pediatrics, Perelman School of Medicine

Overview of Dr. Fisher

Dr. Michael Fisher is a pediatric hematologist/oncologist in Philadelphia, PA and is affiliated with Children's Hospital of Philadelphia. He received his medical degree from Harvard Medical School and has been in practice 23 years. Dr. Fisher accepts several types of health insurance, listed below. He is one of 166 doctors at Children's Hospital of Philadelphia who specialize in Pediatric Hematology & Oncology. He has more than 100 publications and over 500 citings.

Office
3401 Civic Center Blvd
Children's Hospital Of Philadelphia - Hem/Onc
Philadelphia, PA 19104
Book by Phone+1(267) 412-2349

Fax+1 215-590-3992

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1997 - 2000
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1994 - 1997
Harvard Medical SchoolClass of 1994

Certifications & Licensure

PA State Medical License 1997 - 2024
NY State Medical License 2018 - 2020
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma Start of enrollment: 2002 Apr 01
Terminated
Not Applicable
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas Start of enrollment: 2008 Jul 01
Terminated
Phase 1
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27
Active, not recruiting
Phase 2
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children Start of enrollment: 2012 Dec 13
Active, not recruiting
Phase 2
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Start of enrollment: 2014 Jun 01
Completed
Phase 2
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Start of enrollment: 2014 Jun 01
Completed
Phase 2
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Start of enrollment: 2018 Aug 01
Active, not recruiting
Phase 1
Roles: Principal Investigator, Contact
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion Start of enrollment: 2021 Apr 08
Recruiting
Early Phase 1
Roles: Contact
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Start of enrollment: 2023 Apr 10
Recruiting
Phase 2
Roles: Contact
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas Start of enrollment: 2021 Dec 15
Recruiting
Phase 2
Roles: Contact
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Start of enrollment: 2024 Dec 15
Not yet recruiting
Phase 2
Roles: Contact
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma Start of enrollment: 2022 Dec 16
Recruiting
Phase 2
Roles: Contact
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma Start of enrollment: 2024 Jun 15
Not yet recruiting
Phase 2
Roles: Contact, Principal Investigator
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors Start of enrollment: 2022 Nov 21
Recruiting
Phase 1, Phase 2
Roles: Contact
Targeted Pediatric High-Grade Glioma Therapy Start of enrollment: 2024 Jun 28
Not yet recruiting
Roles: Contact
Study of Ribociclib and Everolimus in HGG and DIPG Start of enrollment: 2024 Jun 28
Not yet recruiting
Phase 2
Roles: Contact
Study of Olutasidenib and Temozolomide in HGG Start of enrollment: 2024 Jun 01
Not yet recruiting
Phase 2
Roles: Study Chair, Contact
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion Start of enrollment: 2024 Sep 01
Not yet recruiting
Early Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Low-grade glioma in children with neurofibromatosis type 1: surveillance, treatment indications, management, and future directions.
Chelsea Kotch, Peter de Blank, David H Gutmann, Michael J Fisher
Child's Nervous System. 2024-10-01
2 citations
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international conse...
Patricia O'Hare, Tabitha Cooney, Peter de Blank, David H Gutmann, Mark Kieran
Neuro-Oncology. 2024-08-05
1 citations
Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases.
Britt A E Dhaenens, Günter Heimann, Annette Bakker, Marco Nievo, Rosalie E Ferner
Neuro-Oncology Practice. 2024-08-01

Press Mentions

VIDEO: Study Evaluates Outcomes for Optic Pathway Gliomas Linked to Neurofibromatosis Type 1July 25th, 2024
High Court Allows Employers to Opt Out of ACA’s Mandate on Birth Control CoverageJuly 9th, 2020
High Court Allows Employers to Opt Out of ACA’s Mandate on Birth Control CoverageJuly 8th, 2020
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AmeriHealth Direct POS
AmeriHealth Direct POS Value Network
Amerihealth HMO
AmeriHealth HMO Value Network
AmeriHealth PPO
AmeriHealth PPO Value Network
BCBS Blue Card PPO
BCBS Tennessee Network 5
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Carelink Health Plans PPO
First Health PPO
Great West PPO
HealthAmerica HealthAssurance PPO
Horizon BCBS Direct Access
Horizon BCBS HMO
Horizon BCBS POS
Horizon BCBS PPO
Humana ChoiceCare Network PPO
Humana/ChoiceCare+ Network PPO
IBC Keystone HMO / POS
IBC Personal Choice PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment